Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis
Teva Pharmaceutical Industries Limited is a global generic and specialty pharmaceutical manufacturer headquartered in Israel, with significant operations in the United States and Europe. The company is researched by investors seeking exposure to the generic drug market, which serves as a lower-cost alternative to branded medications and represents a large, recurring revenue stream across healthcare systems worldwide.
Get a full AI research report on TEVA
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Teva Pharmaceutical Industries Limited do?
Teva generates revenue by developing, manufacturing, and distributing generic medicines across multiple dosage forms—tablets, injectables, inhalants, and transdermal patches—as well as specialty branded products in CNS, respiratory, and oncology. The company also produces active pharmaceutical ingredients (APIs), offers contract manufacturing services, and operates an out-licensing platform. Its branded portfolio includes products like COPAXONE (multiple sclerosis), AJOVY (migraine prevention), and AUSTEDO (tardive dyskinesia), which provide higher-margin revenue alongside its core generic business.
Bull case
- ✓Gross margin of 52.1% demonstrates pricing power and operational efficiency in a competitive generic drug market, supporting profitability across its diverse product portfolio.
- ✓Forward P/E of 37.8 is notably higher than trailing P/E of 26.2, suggesting market expectations for earnings growth in coming periods despite current valuation levels.
- ✓PEG ratio of 0.94 indicates the stock may be trading at a discount relative to expected earnings growth, a metric some value investors monitor for growth-adjusted valuation.
- ✓Branded specialty products (COPAXONE, AJOVY, AUSTEDO) provide recurring revenue streams with higher margins and less price competition than generic alternatives.
- ✓Operating margin of 19.2% reflects the company's ability to convert revenue into operating profit, supporting cash generation for debt service and operations.
Bear case
- ✗Debt-to-equity ratio of 205.6 indicates very high financial leverage, meaning the company carries substantial debt relative to shareholder equity and faces significant refinancing and interest-rate risks.
- ✗Quick ratio of 0.527 is well below the 1.0 benchmark, suggesting potential liquidity constraints and limited ability to meet short-term obligations without relying on inventory conversion.
- ✗Generic drug pricing pressure is structural in the industry; increased competition, regulatory pricing controls, and biosimilar adoption can erode margins on core products.
- ✗Forward P/E of 37.8 is substantially elevated compared to the trailing P/E, raising questions about whether near-term earnings growth can justify the premium valuation.
- ✗Return on equity of 21.6% is respectable but must be contextualized against the company's very high leverage; much of the return is amplified by debt rather than operational performance.
TEVA valuation & financial health
Teva trades at a trailing P/E of 26.2 and forward P/E of 37.8, placing it in the mid-to-high range for pharmaceutical companies; the significant gap between the two suggests market expectations for earnings acceleration. The PEG ratio of 0.94 offers a more growth-adjusted perspective, though this depends on the accuracy of growth forecasts. Profitability metrics are solid—gross margin of 52.1%, operating margin of 19.2%, and net margin of 9.0%—indicating the company extracts reasonable profit from its revenue base. However, the debt-to-equity ratio of 205.6 is a critical concern, revealing that Teva is financed primarily by debt; this leverage amplifies both returns and risks. The quick ratio of 1.013 and quick ratio of 0.527 suggest adequate current liquidity but tight short-term cash position, making the company vulnerable to disruptions in cash flow or refinancing challenges. Return on equity of 21.6% appears strong but is largely a function of the high leverage rather than underlying operational excellence.
The bottom line
Teva presents a complex profile for investors to weigh: a profitable, cash-generative business with strong gross margins and a diversified product portfolio, offset by very high debt levels, tight liquidity, and structural headwinds in generic drug pricing. The valuation gap between trailing and forward P/E ratios reflects market optimism about near-term earnings, but this depends on execution and market conditions. Key factors to monitor include debt refinancing activity, generic drug pricing trends, branded product performance (especially COPAXONE exclusivity and new launches), and quarterly cash flow generation relative to debt service. Investors researching Teva should assess their risk tolerance for leverage and their conviction in the company's ability to grow earnings faster than the forward P/E implies.
Frequently asked questions
What does Teva Pharmaceutical Industries Limited do?
Teva develops, manufactures, and distributes generic medicines in multiple dosage forms, as well as specialty branded pharmaceutical products for conditions including multiple sclerosis, migraine, and tardive dyskinesia. The company also produces active pharmaceutical ingredients and offers contract manufacturing services to other pharmaceutical companies.
Is TEVA a good stock to research?
TEVA is relevant for investors interested in generic pharmaceuticals, healthcare exposure, and dividend-free companies with strong operating margins. Whether it merits research depends on your interest in the sector, risk tolerance for high leverage, and views on generic drug pricing trends.
What are Teva's main revenue drivers?
Generic drug sales across multiple therapeutic areas and dosage forms represent the bulk of revenue; specialty branded products like COPAXONE, AJOVY, and AUSTEDO provide higher-margin recurring revenue; and API and contract manufacturing services contribute additional streams.
Is TEVA overvalued or undervalued?
Valuation depends on perspective: the trailing P/E of 26.2 is moderate for pharma, but the forward P/E of 37.8 is elevated, suggesting the market is pricing in significant earnings growth. The PEG ratio of 0.94 suggests growth-adjusted value, but this is only meaningful if growth forecasts materialize.
What are the main risks for TEVA investors?
High debt-to-equity leverage (205.6) creates refinancing and interest-rate risk; generic drug pricing pressure is structural; tight short-term liquidity (quick ratio 0.527) limits financial flexibility; and the company pays no dividend, so returns depend entirely on capital appreciation.
Does Teva pay a dividend?
No, Teva currently pays no dividend (dividend yield of 0% and payout ratio of 0%), meaning the company retains all earnings for operations, debt service, and potential reinvestment rather than returning cash to shareholders.
Research TEVA with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.